Race Oncology Ltd

Based in Sydney, Australia, Race Oncology Limited is an Australian precision oncology firm that commenced operations in 2011. The company's primary focus is the development of Zantrene, a potent small molecule designed to inhibit the fatso/fat mass and obesity associated protein (FTO). This therapeutic agent is currently in Phase II/III clinical trials, exploring its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. Race Oncology actively pursues preclinical research through a program with the University of Newcastle to investigate Zantrene further, and maintains a strategic partnership with the University of Wollongong to assess various formulations of the drug. The company was formerly known as Coronado Resources Limited before adopting its current name, Race Oncology Limited, in July 2016.